Literature DB >> 20491880

MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia.

Kerstin Willander1, Jonas Ungerbäck, Karin Karlsson, Mats Fredrikson, Peter Söderkvist, Mats Linderholm.   

Abstract

BACKGROUND: The single nucleotide polymorphism SNP309 with a change from T to G in the promoter region of the MDM2 gene is shown to increase the MDM2 protein levels and attenuate the p53 levels and associates with disease progression in several tumors.
OBJECTIVE: In this study, the role of the polymorphism was investigated with regard to the clinical outcome in B-cell chronic lymphocytic leukemia (B-CLL). PATIENTS: A total of 210 patients with B-CLL were followed for up to 19 yr.
RESULTS: The overall survival (OS) of patients with at least one G-allele was significantly shorter when compared with those with two T-alleles (P = 0.024) with a more pronounced difference in patients below the median age. Age at onset of B-CLL was similar irrespective of MDM2 status. The presence of a G-allele in combination with TP53 mutations or unmutated IgVH gene status resulted in an additive risk of death.
CONCLUSION: In this report, with a high proportion of B-CLL patients with an advanced Binet stage and with an unmutated IgVH gene, MDM2 SNP309 was found to be independently associated with OS. The survival difference was more pronounced in younger patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20491880     DOI: 10.1111/j.1600-0609.2010.01470.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  5 in total

1.  MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis.

Authors:  Axel Benner; Larry Mansouri; Davide Rossi; Aneela Majid; Kerstin Willander; Anton Parker; Gareth Bond; Sarka Pavlova; Holger Nückel; Olaf Merkel; Paolo Ghia; Emili Montserrat; Mohd Arifin Kaderi; Richard Rosenquist; Gianluca Gaidano; Martin J S Dyer; Peter Söderkvist; Mats Linderholm; David Oscier; Zuzana Tvaruzkova; Sarka Pospisilova; Ulrich Dührsen; Richard Greil; Hartmut Döhner; Stephan Stilgenbauer; Thorsten Zenz
Journal:  Haematologica       Date:  2014-08       Impact factor: 9.941

2.  Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.

Authors:  Ranjan Chrisanthar; Stian Knappskog; Erik Løkkevik; Gun Anker; Bjørn Ostenstad; Steinar Lundgren; Terje Risberg; Ingvil Mjaaland; Gudbrand Skjønsberg; Turid Aas; Ellen Schlichting; Hans E Fjösne; Arne Nysted; Johan Richard Lillehaug; Per Eystein Lønning
Journal:  PLoS One       Date:  2011-04-27       Impact factor: 3.240

Review 3.  Prognostic impact of the MDM2SNP309 allele in leukemia and lymphoma.

Authors:  Sean M Post; Vinod Pant; Hussein Abbas; Alfonso Quintás-Cardama
Journal:  Oncotarget       Date:  2010-07

4.  MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1.

Authors:  Hans Olsson; Per Hultman; Johan Rosell; Peter Söderkvist; Staffan Jahnson
Journal:  BMC Urol       Date:  2013-01-28       Impact factor: 2.264

5.  NOTCH1 mutations influence survival in chronic lymphocytic leukemia patients.

Authors:  Kerstin Willander; Ravi Kumar Dutta; Jonas Ungerbäck; Rebeqa Gunnarsson; Gunnar Juliusson; Mats Fredrikson; Mats Linderholm; Peter Söderkvist
Journal:  BMC Cancer       Date:  2013-06-04       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.